Lead Oncolytic Immunotherapy Program
Metastatic Non-Small Cell Lung Cancer (NSCLC)
Pre-clinicalActive
Key Facts
Indication
Metastatic Non-Small Cell Lung Cancer (NSCLC)
Phase
Pre-clinical
Status
Active
Company
About Accurius Therapeutics
Accurius Therapeutics is a private, pre-clinical stage biotech focused on pioneering a novel oncolytic immunotherapy platform for cancer. The company is developing a targeted treatment for metastatic Non-Small Cell Lung Cancer (NSCLC), a major area of unmet medical need. By integrating advanced viral technology with proprietary delivery systems, Accurius seeks to enhance the potency and specificity of oncolytic virotherapy. The company is led by a team of experienced researchers and commercial leaders, positioning it to advance its lead candidate through development.
View full company profile